公司资料
Quoin 股价、新闻与催化剂
- 股票代码:
- QNRX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.19 USD (+1.96%)
收盘价
最后更新: 2026年8月17日
9.16M USD
市值
股价为何变动
Following the latest company update, “Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results”, QNRX closed down 15.9% at $5.09 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
公司概览
Rare Dermatology Company
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing treatments for rare and orphan dermatologic diseases. Its strategy focuses on conditions with limited or no approved therapeutic options and uses topical formulations intended for chronic administration.
QRX003 in Netherton Syndrome
QRX003, also referred to as QYLEKI, is the company's lead topical program for Netherton syndrome. It has received orphan-drug designation in the United States, European Union, and Japan, as well as FDA Fast Track and Rare Pediatric Disease designations.
Peeling Skin Syndrome Expansion
Quoin is expanding QRX003 into peeling skin syndrome, another rare inherited skin disorder. The FDA has cleared the investigational new drug application for this indication, allowing the company to advance a company-sponsored study in the United States and Europe.
QRX009 Rapamycin Platform
QRX009 is a topical rapamycin formulation platform being explored in rare dermatologic conditions including pachyonychia congenita, Gorlin syndrome, and tuberous sclerosis complex. Quoin plans to use investigator-sponsored work and additional regulatory filings to broaden the platform's clinical reach.
未来催化剂
- Initiation of a Phase 2/3 study of QRX003 in peeling skin syndrome in the second half of 2026.
- Submission of an additional IND for the QRX009 platform by year-end 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。